1. Home
  2. TKNO vs TTRX Comparison

TKNO vs TTRX Comparison

Compare TKNO & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Teknova Inc.

TKNO

Alpha Teknova Inc.

HOLD

Current Price

$2.01

Market Cap

107.1M

Sector

Health Care

ML Signal

HOLD

TTRX

Turn Therapeutics Inc.

N/A

Current Price

$3.35

Market Cap

116.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TKNO
TTRX
Founded
1996
2015
Country
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
107.1M
116.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TKNO
TTRX
Price
$2.01
$3.35
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$8.00
AVG Volume (30 Days)
371.9K
31.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$8.64
N/A
Revenue Next Year
$9.73
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.91
$2.57
52 Week High
$8.65
$26.50

Technical Indicators

Market Signals
Indicator
TKNO
TTRX
Relative Strength Index (RSI) 16.20 31.93
Support Level $1.96 $3.55
Resistance Level $2.26 $3.80
Average True Range (ATR) 0.28 0.27
MACD -0.01 -0.11
Stochastic Oscillator 6.59 2.35

Price Performance

Historical Comparison
TKNO
TTRX

About TKNO Alpha Teknova Inc.

Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.

Share on Social Networks: